Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving hydrolase
Reexamination Certificate
2002-02-28
2003-09-30
Leary, Louise N. (Department: 1654)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving hydrolase
C435S029000, C435S004000
Reexamination Certificate
active
06627411
ABSTRACT:
TECHNICAL FIELD
The present invention relates to a method for evaluating a compound exhibiting matrix metalloproteinase-inhibitory activity for an in vivo matrix metalloproteinase-inhibitory activity displayed by the compound, and specifically to a method therefor which comprises utilizing in situ zymography.
BACKGROUND ART
Matrix metalloproteinase (MMP) is a common name of enzymes which are secreted by cancer cells or normal cells surrounding cancers, and degrade extracellular matrix proteins such as collagen in a divalent metal ions-dependent manner. In particular, it has been frequently reported that type IV collagenases (MMP-2, MMP-9) are responsible for vascularization accompanied by tumor proliferation, and for tumor invasion and metastasis.
As an assay system for measuring matrix metalloproteinase, a gelatin zymography method is known wherein enzyme activities are determined based on degradation degree of a substrate. The method requires conducting electrophoresis, and therefore it is troublesome in the procedures, and time-consuming in the detection.
As an assay system without electrophoresis,
The FASEB Journal
, vol.9, July, pp.974-980, 1995 has proposed a determination method based on the principle of zymography, which comprises incorporating, into agarose, casein or gelatin bound to a fluorescent compound useful as a substrate for the protease, forming the mixture into a thin membrane on slide glass, then placing a tissue section on the surface of a thin membrane, incubating the membrane, and observing the digestion of the substrate by a fluorescence microscopy. The system, however, encounters a trouble with decreased reproducibility, since the agarose affects the digestion of the substrate due to the protease.
Recently, the applicants of the present application proposed a convenient and accurate method for measuring proteases, which comprises contacting a sample containing a protease to a thin membrane formed on the surface of a support, said thin membrane comprising a protease substrate and a hardening agent (WO97/32035), which have received some signs of confidence. For example, Proceedings of 5th Conference of the Japanese Association for Metastasis Research (1996) describes that in situ zymography based on our method was used to detect the gelatinase activity in the tissue and cells, thus observing that the protease destroyed tumor tissues. In situ zymography is described in
The FEBS Journal,
974-980, Vol. 9 (1995) or the like.
Further, H. Nakamura, et al.
Cancer Research
59,467-473(1999) describes that in situ zymography similarly revealed that MMP inhibitors inhibited the MMP activity in human thyroid cancer.
As described above, MMPs, in particular type IV collagenase, are believed to be responsible for vascularization accompanied by tumor proliferation, and for tumor invasion and metastasis. Accordingly, inhibitors of MMPs have been a focus of attention in view of development of anti-cancer agents, and, in fact, some of them are clinically being tested by some pharmaceutical companies.
Pharmacotherapy is achieved on the prerequisite that a drug used in the therapy is effective and safe, and the prerequisite is confirmed by drug evaluation, which is largely classified into two tests, nonclinical test such as animal experimentation, and clinical test wherein human beings are tested. Even agents that are effective in the nonclinical test, or have an excellent action mechanism would not be drugs when the agents are not effective in patients. This is the reason why the clinical test is required to evaluate the drug efficacy in humans.
In drug evaluation of MMP inhibitors by the clinical test, it is difficult to determine exactly the in vivo activity of MMP inhibitors because MMP is inherently controlled in vivo by endogenous inhibitors such as TIMP-1, and -2 [Woessner, J. F. Jr.,
FASEB J.
5, 2145-54 (1991)]. Immunostaining method wherein an antibody specific to MMP is used has been known as a method for detecting MMP (
Int. J. Cancer.,
56, 500-505 (1994)). Since the antibody used therein, however, recognizes MMP in a manner that MMP is merely an antigen protein, this method dose not allow to determine whether an antigen protein recognized by the antibody possesses the MMP activity or is inactivated by the inhibitors. Conventional gelatin zymography dissociates MMP from inhibitors during the electrophoresis, and therefore the method does not also allow the exact determination of the inhibitory activity of MMP inhibitors.
PROBLEMS TO BE SOLVED
In view of the above, the present inventors investigated for a method of checking the in vivo activity of MMP inhibitors, and found that in situ zmography makes it possible to determine conveniently and rapidly the in vivo MMP inhibitory activity of MMP inhibitors.
MEANS TO SOLVE THE PROBLEMS
In the first aspect, the present invention relates to a method for evaluating a compound exhibiting matrix metalloproteinase-inhibitory activity for an in vivo matrix metalloproteinase-inhibitory activity displayed by the compound, which comprises subjecting to in situ zymography a specimen isolated from a mammal that has received the compound.
Specifically, the present invention relates to the method wherein the in situ zymography is conducted using a thin membrane which comprises gelatin or collagen together with a hardening agent, and which has a thickness of 1 &mgr;m to 20 &mgr;m. More specifically, the in situ zymography is conducted by
(1) contacting the isolated specimen onto the thin membrane comprising a substrate of matrix metalloproteinase;
(2) incubating the specimen-thin membrane sample;
(3) staining and then decolorizing the thin membrane; and
(4) verifying the tone developed on the thin membrane.
In the evaluation method of the present invention, it is preferred that the substrate of matrix metalloproteinase is gelatin or collagen; that the thin membrane comprises a hardening agent; that the thin membrane has a thickness of 1 &mgr;m to 20 &mgr;m; and/or that the specimen is a tissue section, preferably a lyophilized tissue section, having a thickness of 2 &mgr;m to 10 &mgr;m, and the incubation is conducted at 20° C. to 50° C., preferably 36 to 38° C., for 2 to 18 hours.
In the second aspect, the present invention relates to a method for evaluating a compound exhibiting matrix metalloproteinase-inhibitory activity for an in vivo matrix metalloproteinase-inhibitory activity displayed by the compound, which comprises:
(1) administering to a mammal a compound exhibiting matrix metalloproteinase-inhibitory activity; (2) isolating a tissue or a fluid from the mammal to prepare a specimen; (3) contacting the isolated specimen onto a thin membrane comprising a substrate of matrix metalloproteinase; (4) incubating the specimen-thin membrane sample; (5) staining and then decolorizing the thin membrane; and (6) verifying the tone developed on the thin membrane.
In the third aspect, the present invention relates to a method for evaluating an anti-cancer agent exhibiting matrix metalloproteinase-inhibitory activity for its anti-cancer activity, which comprises subjecting to in situ zymography a specimen isolated from a mammal that has received the anti-cancer agent, and evaluating for an in vivo matrix metalloproteinase-inhibitory activity displayed by the agent as an indicator of the anti-cancer activity. In the method of the present invention, it is preferred that the substrate of matrix metalloproteinase is gelatin or collagen; that the thin membrane comprises a hardening agent; that the thin membrane has a thickness of 1 &mgr;m to 20 &mgr;m; and/or that the specimen is a tissue section, preferably a lyophilized tissue section, having a thickness of 2 &mgr;m to 10 &mgr;m, and the incubation is conducted at 20° C. to 50° C., preferably 36 to 38° C., for 2 to 18 hours.
It has been known that not only MMP but also many enzymes that degrade gelatin, such as trypsin, exist in the living body. For this reason, it was difficult to determine selectively the activity of MMP inhibitors by manes of in situ zymography using
Maekawa Ryuji
Nemori Rhoichi
Tamura Yutaka
Yoshioka Takayuki
Leary Louise N.
Shionogi & Co. Ltd.
LandOfFree
Method for evaluating matrix metalloprotease inhibitory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for evaluating matrix metalloprotease inhibitory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for evaluating matrix metalloprotease inhibitory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3068850